Posted by Michael Wonder on 23 May 2022
Draft CADTH recommendation for Spinraza (nusinersen sodium) fails adults in need of treatment for spinal muscular atrophy
20 May 2022 - CADTH does not accept new evidence demonstrating Spinraza's effectiveness and safety for treating spinal muscular atrophy – a progressive, life-altering neurodegenerative disease.
Biogen Canada is deeply disappointed for the spinal muscular atrophy community due to the draft recommendation from CADTH that has advised against Sprinraza (nusinersen sodium) reimbursement for adult patients with spinal muscular atrophy.
